New YPrime Report Highlights eCOA's Impact on CNS Trials
May 01 2024 - 8:00AM
YPrime, the leading pioneer in clinical trial technology, today
announced the availability of a new report, Insights into CNS
Clinical Trials, which provides clinical trial sponsors with
data-driven insights on how electronic clinical outcome assessments
(eCOA) can improve Central Nervous System (CNS) trial efficiency
and success. This latest piece of research from YPrime, which has
supported nearly 43,000 patients across more than 16,000 sites,
presents information on leveraging eCOA for faster drug
development, reduced costs associated with lengthy and complex CNS
trials, and access to high-quality data for more informed
decision-making.
With more than three billion people globally affected by CNS
disorders,1 the need for effective treatments has never been more
urgent. Recognizing the critical need to address the unique
challenges of CNS clinical trials and expedite the development of
life-saving neurological therapies, YPrime embarked on a
comprehensive research initiative which culminated in this new
report.
YPrime's Insights into CNS Clinical Trials discusses key
challenges identified by surveyed professionals such as timelines
and delays, patient recruitment and retention, and data quality
concerns. eCOA can help address these pain points by offering
streamlined data collection for faster trial completion,
user-friendly interfaces, and remote monitoring capabilities to
improve patient engagement, compliance, and retention, and
minimizing data entry errors while ensuring consistent scoring for
more reliable data.
"Billions grappling with neurological conditions depend on
advancements in CNS research," stated Mark Maietta, President of
YPrime. "But complex trial designs and complicated outcome measures
can create roadblocks, causing delays and data unreliability. Our
new report provides sponsors with valuable information on
streamlining CNS trials and expediting the development of
treatments. By adopting and optimizing eCOA, sponsors can unlock a
faster path to delivering hope to patients battling CNS
disorders."
- Timelines
and delays are a major hurdle for 60% of respondents, but
eCOA's streamlined data collection can offer faster trial
completion.
- Patient
recruitment and retention are a struggle for 58%, but
eCOA's user-friendly interface and remote monitoring capabilities
can improve patient engagement and compliance, potentially leading
to better rates.
- Data quality
concerns plague 45% of respondents, but eCOA minimizes
data entry errors and ensures consistent scoring, resulting in more
reliable data.
For a complete analysis of the survey findings and a deeper dive
into how eCOA can optimize your CNS clinical trials, download the
complimentary report, Insights into CNS Clinical Trials.
About YPrimeAt YPrime, we streamline the
clinical trial journey with a configurable platform designed for
speed, quality, and certainty. With 50% faster IRT startup times,
up to 30% faster eCOA launch times, and quality standards 50% above
the industry average, YPrime can help you solve for certainty.
Discover how by visiting www.yprime.com or emailing
marketing@yprime.com.
Media
Contact Terry
RehmHead of Thought Leadership and Public Relations,
YPrimetrehm@yprime.com862-288-0329References1 -
The Lancet, March 14, 2024. Global, regional, and national burden
of disorders affecting the nervous system, 1990–2021: a systematic
analysis for the Global Burden of Disease Study 2021.
DOI: doi.org/10.1016/S1474-4422(24)00038-3.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/f92735d6-a1a7-4508-9eae-c5f223456c8e